VALANX has built GoldenSite, a site-specific conjugation platform that places ADC payloads in structurally shielded positions on the antibody, delivering significantly reduced off-target interaction while preserving and enhancing efficacy. Using GoldenSite, we are developing a LIV-1 targeting, differentiated ADC intended to treat metastatic triple-negative-breast cancer.
| Website | https://valanx.bio |
| Employees | 17 (11 on RocketReach) |
| Founded | 2017 |
| Address | Plöcking 1 3400, Klosterneuburg, Lower Austria 3400, AT |
| Technologies |
JavaScript
,
HTML
,
PHP
+15 more
(view full list)
|
| Industry | Biotechnology, Bioconjugation, Science and Engineering, Site-specific conjugation, Medical, PEGylation, Health Care, Pharmaceutical, Research and Development |
| Keywords | Antibody Drug Conjugates, Adc, Biotechnology, Drug Development, Pharmaceutical, Biopharma, Therapeutics, Next Generation Therapeutics, Innovative Therapeutics, Biopharmaceutical Development, Drug Discovery, Pharmaceutical Research, Precision Medicine, Targeted Therapy, Immunotherapy, Biotechnology Solutions |
| Competitors | Novartis, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer, AstraZeneca, Genentech, Amgen, Regeneron, Gilead Sciences, Moderna Therapeutics, Lilly India +35 more (view full list) |
Looking for a particular VALANX Biotech employee's phone or email?
VALANX Biotech Questions
Michael Lukesch is the CEO and Founder of VALANX Biotech.
11 people are employed at VALANX Biotech.
VALANX Biotech is based in Klosterneuburg, Lower Austria.
Top VALANX Biotech Employees
-
23
-
Georg Altenbacher
Chief Business Officer at VALANX Biotech
Vienna, Austria11 -
21
-
Katarina Belačić
Project Lead R and D at VALANX Biotech
Vienna, Austria1 -
Víctor Jiménez Lancho
Scientist at VALANX Biotech
Vienna, Austria1
Related Companies
G2Crowd Trusted
300K+
Plugin Users
